Stryker (NYSE:SYK) Stock Price Target Cut by JPMorgan Chase & Co.

Stryker (NYSE:SYK) had its price objective cut by JPMorgan Chase & Co. from $350.00 to $340.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 16.61% from the company’s current price.

A number of other analysts have also commented on the company. Raymond James Financial reissued an “outperform” rating and set a $323.00 price objective on shares of Stryker in a report on Friday. Citizens Jmp dropped their target price on Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a report on Friday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. BMO Capital Markets reiterated an “outperform” rating and set a $309.00 price target on shares of Stryker in a report on Friday. Finally, Stifel Nicolaus decreased their price target on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Sixteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $355.44.

Stryker Trading Down 0.1%

NYSE:SYK opened at $291.56 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The firm has a 50-day moving average of $292.83 and a 200-day moving average of $324.51. The company has a market cap of $111.83 billion, a PE ratio of 31.05, a PEG ratio of 1.89 and a beta of 0.78. Stryker has a one year low of $267.00 and a one year high of $389.33.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The business had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the prior year, the company earned $3.19 EPS. The company’s revenue was up 7.6% on a year-over-year basis. As a group, equities research analysts expect that Stryker will post 14.85 EPS for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

A number of large investors have recently bought and sold shares of SYK. State Street Corp grew its holdings in Stryker by 1.2% during the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after buying an additional 183,400 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after buying an additional 45,478 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Stryker in the second quarter worth about $1,404,284,000. Royal Bank of Canada boosted its position in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after acquiring an additional 199,863 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after acquiring an additional 481,175 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: JPMorgan lowered its price target from $350 to $340 but maintained an “overweight” rating, implying substantial upside from recent trading levels. Barclays also reaffirmed its “buy” rating, signaling continued confidence in Stryker’s longer-term medical-device prospects. JPMorgan Stryker rating Barclays reaffirms buy rating
• Neutral Sentiment: Analyst sentiment is mixed: Citizens JMP, Citigroup, TD Cowen, and Barclays reportedly trimmed their price targets, while Canaccord Genuity downgraded Stryker to “hold.” The changes reflect more cautious expectations rather than a broad rejection of the company’s fundamentals.
• Negative Sentiment: Stryker’s latest results fell short of forecasts. Adjusted earnings were $3.52 per share versus a $3.55 consensus estimate, while revenue of $6.52 billion missed expectations of $6.62 billion. Although revenue increased 7.6% year over year, the miss and a reset of third-quarter guidance weakened the near-term outlook. Stryker Q3 2026 earnings call transcript
• Negative Sentiment: Health-insurance headwinds were cited as an additional concern, contributing to lower fair-value estimates and multiple price-target cuts. Deutsche Bank reduced its target to $275 from $315 while retaining a “hold” rating. The stock also broke below its 50-day moving average after the disappointing report, adding technical pressure. Stryker stock down on Q3 misses Deutsche Bank adjusts Stryker price target

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.